Pharma will invest $ 50 billion in the United States as stretching of tariff threats

Swiss drug giant Roche On Tuesday gossip In the next five years, the United States will invest $ 50 billion in the United States, it will invest $ 50 billion as a result of concerns about the impaired new white house tariffs in Pharma goods.

The investment will create more than 12,000 jobs, Roche, the rest of the company to support new production capabilities of 1000 – USA. The company said that more than 25,000 people work in America.

Roche shares were 1.1% lower in the morning in London at 8:39.

While Pharma giant, Indiana, Pennsylvania, Massachusetts and California increasing production and expansion facilities, the most modern research and development (R & D) will shoot cash to create sites. Massachusetts will be used for a new brand-outness, AI survey and play a center for research for heart-venture, kidney and metabolism.

Financing package, Roche’s “next generation will be used to build a new 900,000-square-meter production center in an unknown place to support the portfolio of weight loss medicines.

After the completion of the new production potential, Roche said he would export more drugs than the United States.

Pharmaceutical companies rubbed the United States to increase the presence of US threats Free Donald Trump to release the industry from the import tariffs.

“We will declare a very short large tariff on the pharmacy,” he said This month ago said.

Roche’s investment follows similar actions from large competitors. Swiss Novartis in the beginning of this month declared $ 23 billion in the building in the $ 23 billion building and expanding 10 US will create more than 4,000 jobs in this move.

English Pharmaceutical Giant AstraZeneca Last Moth gossip Beijing said he would invest $ 2.5 billion to create a hub. However, the company’s CEO Pascal Soriot told CNBC to CNBC as Astrazeneca “very committed to the United States”, which is “very loyal to the United States,” he said.

Roche CEO Thomas Scinecker, in a statement on Tuesday, the company’s new $ 50 billion investment showed “Long-time in the United States for a long time for development and production.”

“We are proud of the main driver in the United States, but also the 110-year heritage in the United States, which creates intellectual property on both pharmaceutical and diagnostic sections,” he said. “Our $ 50 billion investment in the next five years will lay the basis of innovation and growth period to benefit from the United States and the world.”